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ABSTRACT 
Objective: The aim of present study was to prepare nanostructured lipid carriers (NLCs) based Triamcinolone acetonide (TA).  
Methods: Nanostructured lipid carriers (NLCs) consisted of solid lipid and liquid lipid are a new type of lipid nanoparticles, prepared by using 
solvent diffusion and high pressure homogenization methods, which offer the advantage of improved drug loading capacity and release properties. 
Glyceryl monostearate selected as the solid lipid, capmul MCM C8 as the liquid lipid, polyvinyl Alcohol (PVA) as the surfactant. NLCs dispersion was 
characterized by particle size analysis, zeta potential, scanning electron microscopy (SEM), differential scanning calorimetry, and an in vitro release 
study. 
Results: Optimized NLCs loaded with TA were exhibited spherical shape with particle size 286.1 nm, polydispersity index 0.317, zeta potential-21.9 
mV and entrapment efficiency 86.19% respectively. The result of differential scanning calorimetry (DSC) showed that drug was dispersed in NLCs in 
a crystalline state. In vitro release studies revealed that drug release of optimized batch was 8.34 % and 88.84% at 1h and 8h respectively. The 
release kinetics of the optimized NLCs best fitted the peppas-korsmeyer model. Furthermore, morphological investigations by SEM showed that 
optimized batch exhibit a spherical shape and a smooth surface.  
Conclusion: Thus, the results indicated that successfully prepared TA-loaded NLCs and could potentially be exploited as a carrier with improved 
drug loading capacity and sustained drug release. The present results demonstrated that these systems could be a promising platform for 
inflammatory diseases, in particular for psoriasis topical therapy.  
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INTRODUCTION 
Now days, nanotechnology has proved the growth of research and 
its applications in the area of medicine [1]. Since last decade, various 
techniques have been studied to formulate nanoparticulate carrier 
systems. Polymeric and solid lipid nanoparticles (SLNs) are two 
varieties of nanocarrier systems. Polymeric nanoparticles suffered 
with some drawbacks such as toxicity and unavailability of good 
techniques for production of nanoparticles at large scale. Compared 
to polymeric nanoparticles, SLNs gain advantages in terms of less 
toxicological risk because of natural origin lipids. Despite SLNs being 
good carriers, less capacity of drug loading and expulsion of the drug 
during storage, may require some good technique to overcome such 
problems. As an effect, nanostructured lipid carriers (NLCs) have 
been developed, which in some extent can avoid the afore 
mentioned limitations.  
NLCs was second generation of SLNs having solid lipid and liquid 
lipid matrix that create a less ordered or imperfect structure, which 
helps in improving drug loading and decreasing the drug expulsion 
from the matrix during storage period. The development of 
nanocarrier systems is an approach to overcoming such problems 
[2, 3]. NLCs composed of a solid lipid matrix with a certain content 
of liquid lipid are a new generation of SLNs [4]. The advantages of 
these systems are, stabilize oxidation/photo-sensitive materials by 
incorporating poorly water soluble drugs. As dermally applied, 
ensure close contact with the lipid bilayer of the stratum corneum, 
resulting in a more efficient and deeper drug penetration into the 
skin layers [5, 6]. 
Corticosteroids are the most widely used in the treatment of 
dermatological disorders is related to their vasoconstrictive, anti-
inflammatory, immunosuppressive and anti-proliferative effects [7, 
8]. Triamcinolone acetonide (TA) is a synthetic glucocorticosteroid 
binds in the target cell to specific cytosolic glucocorticoid receptors 
and subsequently interacts with glucocorticoid receptor response 
elements on DNA, thereby altering gene expression [9]. NLCs are 
composed of biodegradable and physiological lipids as a carrier, 
exhibiting low systemic cytotoxicity [10-12]. 
In case of dermatological diseases such as psoriasis, whose triggers 
are situated beneath the skin, it is preferable to manage drugs 
topically rather than systemically due to more efficient direct action 
with improvement of the local access for optimum amount of drug. 
Topical administration also reduces the systemic burden and toxic 
effects of the drugs and it is considered the first line of treatment 
used in moderate psoriasis as it is considered safe and well accepted 
by the patients [13, 14]. The successful implementation of these 
systems for drug delivery entirely depends on their ability to go 
through numerous anatomical barriers, sustained release of their 
content and stability in the nanometer size [15, 16]. Various 
particulate lipid based colloidal carriers have also found application 
in anti-psoriatic drug delivery, in particular SLNs and NLCs [17].  
Lipid based drug delivery systems are now days popular because of 
their potential to increase solubility and bioavailability of poorly 
water soluble drugs. This becomes an important tool, when it is 
necessary to supply the drug over a prolonged period of time, and to 
reduce systemic absorption, when the drug is irritating in high 
concentrations. NLCs have the potential to adjust the drug release 
over an extended period with a reduced rate of systemic absorption. 
The lipid film formation above the skin and the succeeding occlusion 
effect was described for lipid nanoparticles with reduction of 
transepidermal water loss caused by this effect, leads to an augment 
in skin hydration after dermal application of SLNs or NLCs [18-21]. 
NLCs systems are a promising carrier for the topical delivery of 
antipsoriatic drugs as revealed by improved skin permeation and 
reduce irritation, narrow size distribution, better bioavailability and 
the compatibility of the drugs. 
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The present investigation explored the possibility of NLCs as a 
unique carrier system for the topical application with regard to the 
modulation of release of TA. Solvent diffusion method has 
remarkable advantages such as use of simple equipment accessories, 
easiness in handling and quick manufacturing [22]. The aim of 
present research work was to develop stable TA loaded NLCs 
formulation using solvent diffusion method and to evaluate in vitro 
characteristics of prepared formulation.  
MATERIALS AND METHODS 
Materials 
Triamcinolone acetonide and Capmul MCM C8 were obtained as a 
gift samples from Glenmark Pharmaceuticals, Goa and Abitec 
Corporation, Janesville, USA respectively. Glyceryl monostearate, 
polyvinyl alcohol and carbopol were purchased from Loba 
Chemicals, Mumbai, India. All other solvents and reagents used in 
this work were of analytical/HPLC grade. 
Methods 
The sample of TA was analyzed for its nature, color and taste. The 
melting point was performed by using open capillary method. TA 
was estimated by UV spectrophotometry method. Calibration of TA 
was carried out by preparing different stock solution in methanol 
(10µg/ml to 50µg/ml) to determine concentration from absorbance.  
Optimization of formulation using factorial design 
A statistical model incorporating interactive and polynomial term 
was used to evaluate the responses. 
Y = b0+b1X1+b2X2+b11X1 2+b22X22+b12X1X2
Where, Y is dependent variable, b0 is the arithmetic mean 
response of the 9 runs, and bi (b
 (Eq.1) 
1 , b2, b 12 , b 11 and b 22 is the 
estimated coefficient for the factor X 1). The main effect (X1 and 
X2) represents the average results of changing one factor at a time 
from its low to high values. The interaction term (X1X2) show how 
the response changes, when 2 factors are changed simultaneously. 
The polynomial term (X12 and X22
The effect of the variables were investigated on the responses of the 
particle size and entrapment efficiency, were selected as dependent 
variables and drug and lipid concentration (X
) are included to investigate 
nonlinearity. The formulations were fabricated according to a 3² 
full factorial design, allowing the simultaneous evaluation of two 
formulation independent variables and their interaction. 
1) and stabilizer 
concentration (X2
Factorial design parameters and experimental conditions are the 
factors used drug and lipid concentration levels 35, 40 and 45 in mg 
and stabilizer concentration levels 240, 260 and 280 in mg. Factorial 
designs formulation and experimental conditions factors levels used 
shown in table 1 and 2. 
) as independent variables. The replicate 
experimental runs were carried out in complete randomized 
manner. A multilinear stepwise regression analysis was performed 
using microsoft excel software. The full models were used to plot 
two-dimension contour plots for both particle size and entrapment 
efficiency. All the statistical operations were carried out by PCP 
Disso 2000 V3 software.  
 
Table 1: 32
Batch code 
 Factorial designs formulation 
Coded values 
*X1 *X2 
B1 -1 -1 
B2 -1 00 
B3 -1 +1 
B4 00 -1 
B5 00 00 
B6 00 +1 
B7 +1 -1 
B8 +1 00 
B9 +1 +1 
*X1-Amount of drug and Capmul MCM C8, *X2-Amount of GMS and PVA, *-1, 0,+1–Low, Medium and High amount of drug and Capmul MCM C8 and 
GMS and PVA 
 
Table 2: Amount of variables in a 32 
Coded values 
factorial design formulation 
 
Actual values 
Amount of drug and capmul MCM C8 X1 (mg) Amount of GMS and PVA X2 (mg) 
-1 35 240 
0 40 260 
+1 45 280 
 
Table 3: Composition of NLC batches 
Ingredient Batches code 
B1 B2 B3 B4 B5 B6 B7 B8 B9 
Drug (mg) 12 12 12 12 12 12 12 12 12 
Capmul MCM C8(µl) 23 23 23 28 28 28 33 33 33 
Glyceryl mono stearate (mg) 57 57 57 57 57 57 57 57 57 
Polyvinyl alcohol (gm) 0.183 0.203 0.223 0.183 0.203 0.223 0.183 0.203 0.223 
 
Preparation of NLCs 
NLCs loaded with TA were developed using solvent diffusion 
method in aqueous system. Briefly, 228 mg mixture of capmul MCM 
C8 and GMS with 12.5,25 wt% lipid content, prepared by adding 
capmul to GMS and 12 mg of TA, total weight of 5% w/w to the drug 
and lipids were mixed in a solvent mixture of ethanol (6 ml) and 
acetone (6 ml) that is (1:1 v/v) kept in sonication bath (Spectra lab 
model UCB 70) for 10 min. and on water bath temperature was 
maintained at 60 °C. GMS was added to resultant mixture to make it 
clear solution of lipid and drug in organic solvent system. The 
aqueous phase of PVA (0.2%) used as stabilizer made up to 100 ml 
into which the organic mixture was added and kept on water bath, 
maintained temperature at 70 °C and processed under mechanical 
agitation of 500 rpm for 10 min. using mechanical stirrer (IKA RW 
20 Digital). At room temperature TA loaded NLCs dispersion was 
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cooled for 20 min. The dispersion was kept on magnetic stirrer for 
liberation of organic solvent. Obtained dispersion was mixed by 
using Ultra turrex homogenizer for 10,000 rpm for 5 min. Further 
samples were passed through High pressure homogenizer under 
pressure of 1000 bar and 30 cycles. NLCs dispersion was dried in 
freeze drier by adding cryoprotectant (mannitol) and lyophilized, 
obtained a dried and free flowing powder [23, 24]. Composition of 
NLCs batches were shown in table 3. 
Characterization of NLCs formulations 
Particle size and zeta potential 
The particle size distribution and zeta potential of the prepared 
NLCs were measured by using Horiba SZ-100 using dynamic light 
scattering (DLS). Particle size and particle size distribution of the 
NLCs determined by using particle size analyser, after dilution with 
water determine the diameter and mean particle size distribution. A 
light is passed into the cell, at 90° or 173°. Depending on both the 
concentration of sample and strength of the system, selects the 
optimum scattering angle and cell position. 1 ml of sample was 
injected into the zeta cell and measurements for the zeta potential 
analysis. Zeta potential is a measure surface charge of particles and 
thus it imparts the colloidal stability due to particle-particle 
repulsion, as particle aggregation is less to occur for charged 
particles having high zeta potential. 
Percentage entrapment efficiency 
A 5 ml sample of NLCs dispersion was centrifuged at 8,000 rpm at 
10 °C for 20 min. by using cooling centrifuge. The supernatant was 
separated, and then resuspended the NLCs lipid layer in methanol 
and centrifuged. This washing process was repeated two times to 
guarantee that the free drug was no longer present in the voids 
between the NLCs. The collected NLCs residue was lysed with 
absolute methanol. TA in the supernatant was determined by UV 
spectrophotometric method at specified wavelength. The % 
entrapment efficiency was calculated by using formula 1. 
% Entrapment efficiency = Tp − Tf
Tp
 X 100[1] 
Where, Tp is the total amount of drug, Tf amount of drug in 
supernatant 
In vitro release study 
In vitro release of TA from NLCs was evaluated by the dialysis diffusion 
technique. The diffusion medium was used phosphate buffer pH 7.4. 
NLCs equivalent to 1 mg of TA was dissolved in buffer, placed in the 
dialysis bag and sealed at both the ends. The dialysis bag was 
immersed in 70 ml of the receptor compartment (beaker), which was 
stirred at 50 rpm and maintained temperature at 37±2 °C. The 
receptor compartment was covered to prevent the evaporation of 
medium. A 5 ml sample was withdrawn at every 15 min. interval for 
first 1h and 1h interval for next 8h. The same volume was replaced by 
dissolution medium in the flask to maintain a constant volume. The 
samples were filtered, suitably diluted and % cumulative drug release 
determined by UV spectroscopy at λ max of 238 nm.  
Fourier transform infrared spectroscopy (FTIR) 
FTIR spectrum shows the fundamental peaks corresponding to the 
chemical nature of the drug and excipients. FTIR studies were carried 
out in order to determine the possible interaction among drug and 
excipients used. IR absorption spectrum of TA was determined by 
fourier transform infrared spectrophotometer Perkin Elmer (Brooker) 
at resolution of 2-1 cm. Spectra were recorded over the wave number 
400-4000 cm-1. Infrared spectrums of pure drug and optimized 
batches were recorded. From the spectrum analysis the compatibility 
of ingredients in the formulations were determined. The infrared 
spectrum of TA was recorded and determine the chemical component, 
which present at specified wavelength.  
Differential scanning calorimetry (DSC) 
DSC studies were carried out using (Mettle-Toledo DSC821 
instrument). Indium and zinc standards were used to calibrate the 
DSC temperature and enthalpy scale. Freeze dried of NLCs optimized 
batch and pure drug were hermetically sealed in aluminium crucible 
and heated at 10 °C/min over a temperature range of 0-450 °C. An 
inert atmosphere was maintained by purging with nitrogen at a flow 
rate of 50 ml/min. An empty aluminium pan was used as standard 
reference. Thermograms of pure TA, physical mixture and NLCs 
formulation were obtained using DSC. 
Powder X-ray diffraction (P-XRD) 
The XRD patterns were recorded on X-ray diffract meter (PW 1729, 
Philips, Netherlands). Samples were irradiated with 
monochromatized Cu-Ka radiation (1.542A˚) and analyzed from 2 °-
100° 2θ at a scan speed of 0.1° 2θ/sec using 1.524 A˚ radiations. The 
spectra of XRD are recorded and analyzed. 
Scanning electron microscopy (SEM) 
SEM analysis was carried out by using ESEM (QUANTA-200-3D, FEI, 
USA) at 20.0KV in environmental mode for identification and 
morphology of NLCs. Thin film of test was set up on carbon covered 
copper network by simply dropping a one drop of test on 
framework, test was expelled by channel paper/tissue paper and 
allow drying a sample for overnight. Before taking an image, coat the 
grid by gold coating, and observe the size and morphology of 
particle.  
Stability study 
Stability studies were carried out according to ICH guidelines Q1A 
(R2
RESULTS AND DISCUSSION 
). The stability of NLCs was calculated by storing the sample for a 
period of 30 d at 40±2 °C/75±5% temperature and relative humidity 
respectively. Samples were removed at interval of 1 mo and 
examined for particle size, zeta potential, and % entrapment 
efficiency. 
The sample of TA was amorphous powder having white color, 
odorless and bitter in taste. The melting point was observed in the 
range of 292 °C-294 °C. The standard solution of TA was scanned 
through 200-400 nm wavelength on Shimadzu UV-1800 
spectrophotometer. The TA absorption maximum was found to be 
238 nm. The obtained NLCs have been assessed for particle size 
analysis, zeta potential, entrapment efficiency and solid state 
characteristic by XPRD, DSC, FTIR and SEM analysis. 
Selection of surfactant and its concentration 
Liquid lipid was selected based on the maximum solubility of the 
drug in different solvent. Lipids were used for the study, capmul 
MCM C8, isopropyl myristate, oleic acid, labrafil ILM 1944 CS and 
labrafec CC. Selection of best surfactant from tween 20, tween 80, 
span 20, span 80 and PVA on the basis of its particle size and 
polydispersity index. For each surfactant of 1.0% concentrations 
was prepared and fixed stirring speed at 1000 rpm. The 
concentrations of surfactants were optimized according to the 
resultant particle size and polydispersity index of each batch. When 
surfactant tween 20 was used, particle size and PDI observed 
396.4±0.95 nm and 0.325±0.002 as compared to tween 80, 
425.95±5.05 nm and 0.355±0.04 and PVA 286±6.35 nm and 
0.317±0.03 respectively. PVA was used as surfactants for 
stabilization of nanolipids more effectively with smallest particle 
size and narrowest particle size distribution, observed as compared 
to tween 80 and tween 20. Hence PVA was selected as a surfactant 
for further development of nanolipid carrier formulation with 
smallest particle size. 
Preparation and characterization of NLC  
NLCs loaded with TA were developed using solvent diffusion 
method in aqueous system. 
Particle size and polydispersity index 
The formulated NLCs sizes were analyzed using DLS, results revealed 
that presence of NLCs mean diameter of optimized batch was about 
286.1 nm, maximum NLCs lie between size ranges of 200-500 nm with 
an average particle size was 286.1 nm with polydispersity index 0.317. 
Particle size of optimized batch shown in fig. 1. 
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Fig. 1: Particle size of optimized batch 
 
Zeta potential 
Zeta potential of the NLCs was determined by using zeta sizer. NLCs 
with zeta potential±30mV were considered as highly stable. The zeta 
potential of optimized batch B6 was obtained-21.9 mV which 
correspond to stability of formulation. The zeta potential in the 
range of-14.30 to-21.9 mV was obtained of all prepared batches. The 
results of zeta potential of all batches and optimized batch were 
shown in table 4 and fig. 2. This finding is in agreement with that 
published by Salunkhe SS et al. [1]. 
 
 
Fig. 2: Zeta potential of optimized batch 
 
Entrapment efficiency 
The % entrapment efficiency of NLCs was found to be in the range 
of 75.2% to 86.19 %. The entrapment efficiency of the optimized 
batch B6 was 86.19% because of the perfect ratio of lipid volume 
in the vesicles as compared to other batches. Thus, it shows the 
effect of capmul, PVA and edge activators ratios on entrapment 
efficiency. The % entrapment efficiency of all batches were shown 
in table 4. This finding is in agreement with that published by 
Salunkhe SS et al. [1]. 
 
Table 4: Optimized batches of NLC formulation 
Batches code X1 X2 Particle size Entrapment efficiency Zeta Potential 
B1 -1 -1 389 83.06 -14.54 
B2 -1 0 370 82.07 -15.01 
B3 -1 +1 360 81.03 -17.45 
B4 0 -1 386 82.16 -14.30 
B5 0 0 350 84.45 -18.26 
B6 0 +1 286 86.19 -21.91 
B7 +1 -1 410 78.03 -15.20 
B8 +1 0 394 76.01 -16.89 
B9 +1 +1 362 75.02 -18.25 
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Development of polynomial equations 
The experimental design and parameters shown in table 1 and 2 for 
factorial formulations B1 to B9, polynomial equations for two 
dependent variable particle size and entrapment efficiency derived 
by using PCP Disso 2000 V.3 software. The response surface plots of 
effects of TA and capmul, PVA on particle size and entrapment 
efficiency are shown in fig. 3 and 4 respectively. The multiple 
regression equation relating the response particle size and 
entrapment efficiency to transformed factors were given in 
equations 2 and 3 respectively. 
PS =347.233+6.8417X1-31.5000X2+39.1750X12–9.8500X22
(R
-6.0500X1X2 
(Eq.2)  
2
%EE = 84.2827-2.8022X1-0.1683X2-5.0155X1
= 0.88161) 
2–0.0240X22
(R
-0.2820X1X2 
(Eq.3)  
2
The polynomial equation can be used to draw conclusion after 
considering the magnitude of coefficient and the mathematical sign 
it carries, (i.e., positive or negative). 
= 0.87479) 
  
 
Fig. 3: Response surface plot for particle size 
 
 
Fig. 4: Response surface plot for entrapment efficiency 
 
In equation 2, negative sign for coefficient of X2 indicate that the 
particle size of NLCs increases, when concentration of PVA was 
decreased and positive sign for coefficient of X1 indicate the positive 
effects of drug and capmul concentration on particle size. In 
equation 3, negative sign for coefficient of X1 indicate that % 
entrapment decreases, when concentration of drug and capmul 
increases and negative sign for coefficient of X2 indicate that % 
entrapment increases, when concentration of PVA decreases.  
The closeness of predicted and observed values of particle size and % 
entrapment indicates the validity of derived equations for dependent 
variable. The data clearly indicate that the particle size and entrapment 
efficiency were strongly dependent on the selected independent 
variables. The values of the correlation coefficient indicate good fit. 
The response surface plots illustrate that as concentration of drug and 
capmul increases, the value of dependent variable, particle size 
decreases and concentration of PVA increases the values of dependent 
variable, particle size decreases. Similarly, the response surface plots for 
% drug entrapment shows negative effects of independent variable, drug 
and capmul concentration and PVA concentration. The data demonstrate 
that both drug, capmul (X1) and PVA (X2) affect the drug release, particle 
size and entrapment efficiency. It concluded that the high levels of X1 and 
X2 favor the drug release and hence particle size was less as compared to 
the low levels of X1 and X2. Findings are in accord with those concluded 
in many relevant works [10, 12]. 
In vitro drug release study 
The cumulative percentage drug release of batches B1 to B9 were in 
the range of 72.59 to 88.84% for 8 h. The percentage release of 
optimized batch was found to be 8.34 % and 88.84 % at 1 h and 8 h 
respectively. In vitro drug release study of TA loaded NLC was 
indicated sustained release for 8 h. The % cumulative drug release of 
drug of all batches were shown in fig. 5. This finding is in agreement 
with that published by Dixit CM et al. [20]. 
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Fig. 5: % Cumulative drug release of drug 
 
FTIR spectroscopy study 
The FTIR study was carried out to confirm the compatibility between 
selected drug and excipients. Spectrums of TA were showed 
characteristics peaks belonging to measure functional groups such as 
principle peaks at wave numbers 1710 cm-1, 3343 cm-1and 1660 cm-1
 
. 
The observed peaks and possible functional groups for TA, physical 
mixture and NLCs optimized batches were shown in fig. 6, fig. 7 and fig. 8 
respectively. The major IR peaks observed in TA were 1710 (1710-
1720) (C=O), 3343 (3300-3400) (O-H), 1660 (1660-1820) (C=O). 
 
Fig. 6: FTIR spectral analysis of TA 
 
The major IR peaks of physical mixture (PVA+drug) were observed, 
3396 (3550-3200) (O-H),1708(1750-1680)(C=O),1662(1690-
1630)(C=O),1611(1700-1500)(C=C)1278,1215(1320-1210)(C=O), 
1079(1200-1025)(C-N), 1079,1056(1200-1025)(C-N)cm-1
 
. 
 
Fig. 7: FTIR spectral analysis of physical mixture 
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The major IR peaks of NLCs were observed, 3265 (3550-3200) (O-
H), 2936 (2950-2800) (C-H)1460(1600-1450) (C=C),1088, 
1022(1260-1000)(C-O),831,890(890)(C-H),and 718(780-690)(C-H) 
cm-1
 
. 
 
Fig. 8: FTIR spectral analysis of NLCs 
 
FTIR results reveals that the fundamental peaks of the TA were 
retained in the optimized batch B6 formulation. Results showed that 
no major changes as well as no loss of functional peaks. This 
indicates that absence of chemical interaction or any changes 
between TA and excipients used in the formulation. 
X-ray diffraction study 
The diffraction spectrum of TA showed that the drug was crystalline 
nature indicated by numerous, relative sharp and distinct peak at 
diffraction angle 2θ shown in fig. 9. The results indicated that XRD 
spectrum of NLCs batch shown reduced peak intensity it leads to 
reduced crystallinity. It revealed that the there was no such interaction 
observed in excipients and polymer used. In XRD analysis all peak 
intensity was observed in decreasing order, therefore the NLCs 
formulation shows decrease in crystallinity. The overlain of diffraction 
spectrum of XRD of A) drug B) physical mixture C) NLCs shown in fig. 9 
Differential scanning calorimetry (DSC) 
The DSC curve of TA shows a broad endotherm indicating single, 
sharp melting endotherm peak at 191.6 °C, which corresponded to 
its intrinsic melting point indicating it’s crystalline nature. 
Thermogram of physical mixture showed almost the same peaks of 
drug at 191.6 °C. However, no sharp endotherm was seen at 161.6 °C 
and 170 °C for NLCs optimized batch B6, it suggesting that TA in 
NLCs was molecularly dispersed as a less crystalline form, it’s 
melting point was decreased indicating reduced crystallinity due to 
dilution effect of the polymers. DSC results were support of the XRD 
analysis, which also shows decrease in drug crystallinity in NLCs 
formulation. The overlain of drug, physical mixture, NLCs optimized 
batch B6 were shown in fig. 10. Findings are in accord with those 
concluded in many relevant works [1, 12]. 
Scanning electron microscope (SEM) 
The results of SEM can be revealed that TA showed needle shaped 
large crystals, indicating crystalline nature. However, the prepared 
NLCs optimized batch B6 had a drastic change in morphology, nearly 
spherical shape with nonporous and smooth surface observed under 
2500X and 18kv, so no drug crystals were present in NLCs 
formulation. The SEM of pure TA and optimized batch B6 shown in 
fig. 11 and 12 respectively. Thus, prepared NLCs confirm stability in 
their structure and shape. Findings are in accord with those 
concluded in many relevant works [4, 10, 24]. 
 
 
Fig. 9: Overlain XRD of A) Drug B) Physical mixture C) NLC 
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Fig. 10: Overlain of drug, physical mixture, NLC 
 
 
Fig. 11: Scanning electron microscopy of TA 
 
 
Fig. 12: Scanning electron microscopy of NLC optimized batch 
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Stability study 
Stability studies of TA-NLCs was evaluated based upon of physical 
properties obtained. Over a period of 30 d, under specified 
conditions of temperature and relative humidity, the results reveals 
that no morphological changes observed but particle size, PDI was 
found to be increased. However, zeta potential remains almost 
unchanged for TA-NLC indicating stability of the structure in 
formulation. Thus, it concludes that the drug does not undergo 
degradation on storage. Stability study of optimized batch B6 for 
particle size shown in fig. 13. Findings are in accord with those 
concluded in many relevant works [4, 10]. 
 
 
Fig. 13: Stability study of optimized batch for particle size 
 
CONCLUSION 
The present study was to prepared NLCs formulation loaded with 
TA by solvent diffusion method using a 32
DSC and XRD studies confirm the transformation of crystaline 
nature of drug into amorphous that plays an important role in 
enhancement of absorption rate followed by bioavailability. SEM 
study confirms nanosized discrete spherical shape with smooth 
surface area. Optimized formulation at room condition shows 
extremely stable formulation for the period of one month that 
support the fact that dried lyophilized nanocarriers may remain 
stable for longer period of time. It was concluded that the 
development of NLCs formulation could potentially be exploited as a 
carrier with improved drug loading capacity and controlled drug 
release properties. Thus, TA loaded NLCs formulation can be 
beneficial in treatment of psoriasis.  
 full factorial design. 
Compared to SLNs, the NLCs exhibit high entrapment efficiency with 
sustained release of drug up to the period of 8h. It showed improved 
drug loading capacity and a good ability to reduce the drug 
expulsion on storage. For optimized batch B6, particle size, % 
entrapment efficiency and zeta potential were 286.1 nm, 86.19 and-
21.9 mV respectively. The % cumulative release of optimized batch 
B6 was found to be 8.34 % and 88.84 % at 1 h and 8h respectively. 
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